Navigation Links
Amgen and Onyx Pharmaceuticals Announce Upcoming Data Presentations at 55th American Society of Hematology Annual Meeting
Date:11/7/2013

onday, December 9, 5:00 pm CT, 393-394
  • Oral presentation: Myeloma: Therapy, excluding Transplantation II
  • Abstract # 687
  • Phase II Clinical and Correlative Study of Carfilzomib, Lenalidomide, and Dexamethasone (CRd) Followed by Lenalidomide Extended Dosing (CRD-R) Induces High Rates of MRD Negativity in Newly Diagnosed Multiple Myeloma (MM) Patients

    • Dr. Neha Korde, Multiple Myeloma Section, National Cancer Institute, National Institutes of Health
    • Monday, December 9, 3:30 pm CT, 393-394
    • Oral presentation: Myeloma: Therapy, excluding Transplantation: Treatment Options for Newly Diagnosed Multiple Myeloma Patients
    • Abstract # 538

    Serum Heavy-Light Chains (HLC) and Free Light Chains (FLC) As Predictors For Early CR In Newly Diagnosed Myeloma Patients Treated With Carfilzomib, Lenalidomide, and Dexamethasone (CRd)

    • Dr. Manisha Bhutani, Multiple Myeloma Section, National Cancer Institute, National Institutes of Health
    • Monday, December 9, 7:30 pm CT, 393-394
    • Oral presentation: Myeloma: Therapy, excluding Transplantation: Advances in Multiple Myeloma and Plasma Cell Leukemia
    • Abstract # 762

    Phase I/II Dose Expansion of a Multi-Center Trial of Carfilzomib and Pomalidomide with Dexamethasone (Car-Pom-d) in Patients with Relapsed/Refractory Multiple Myeloma

    • Dr. Jatin Shah, The University of Texas MD Anderson Cancer Center
    • Monday, December 9, 5:45 pm CT, 393-394
    • Oral presentation: Myeloma: Therapy, excluding Transplantation II
    • Abstract # 690

    Carfilzomib, Rituximab and Dexamethasone (CaRD) is highly active and offers a neuropathy sparing approach for proteasome-inhibitor based the
    '/>"/>

    SOURCE Onyx Pharmaceuticals, Inc.; Amgen
    Copyright©2012 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7 8 9 10

    Related biology technology :

    1. Amgen and FDA Agree to Modify Nplate® (Romiplostim) Risk Evaluation and Mitigation Strategy
    2. Amgen Presents Final Results from the Largest Phase 3 Open-Label Study Assessing the Safety and Efficacy of Nplate® (Romiplostim)
    3. Amgen Announces 2012 First Quarter Dividend
    4. Kevin Sharer, Amgen Chairman and CEO, Announces Plan to Retire With Robert Bradway to Become CEO on May 23, 2012; Sharer Will Continue as Chairman of the Board Until End of 2012
    5. Amgen to Present at the 30th Annual J.P. Morgan Global Healthcare Conference
    6. Amgen Announces Webcast of 2011 Fourth Quarter and Full Year Financial Results
    7. Amgen to Acquire Micromet
    8. Amgen to Present at the Leerink Swann Global Healthcare Conference
    9. Amgen Announces 2012 Third Quarter Dividend
    10. Amgen Names Ray Jordan Senior Vice President, Corporate Affairs
    11. Amgen To Present At The 24th Annual Piper Jaffray Healthcare Conference
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:7/29/2014)... The first product launch from start-up Hurley Research ... What sets Droidles completely apart from other stand alone ... to communicate, share code with each other and evolve ... invention is the system,” said Hurley Research founder Jay ... their own, both physically and on the internet." Remote ...
    (Date:7/29/2014)... The prestigious "Discovery or Exploration in ... awarded to Juliana Hillis and Kaylie O’Connell, students at ... “From an Egg, Everything: America’s First IVF Baby". This ... the National History Day program during a week-long final ... in Washington, D.C. , The growing popularity of the ...
    (Date:7/29/2014)... CA (PRWEB) July 29, 2014 ... medical devices, and cloud based eClinical technologies, have been ... Device Online. These follow a long line of white ... profile publications including Life Science Leader, Pharmaceutical Online, and ... Clinovo provided a paper by CTO Marc Desgrousilliers, ...
    (Date:7/29/2014)... , July 29, 2014 ... System (LBS) zur Erfassung biologischer Daten in ... entwickelt und patentiert. Das LBS nimmt gleichzeitig ... Koronararterie des Patienten und sucht erhöhte biologische ... das Potenzial, die Entdeckung und Entwicklung neuer ...
    Breaking Biology Technology:Droidles, the Social Network of Robots and Open Source Platform for the Internet of Things, Launches for Crowd Funding on IndieGoGo.com 2In Vitro Fertilization (IVF) was the Subject of This Year’s Winning Entry for the Prestigious Library of Congress “Discovery or Exploration in History Award” 2In Vitro Fertilization (IVF) was the Subject of This Year’s Winning Entry for the Prestigious Library of Congress “Discovery or Exploration in History Award” 3Clinovo White Papers Published in Summer 2014 Editions of Leading Medical Device & Pharmaceutical Publications 2Clinovo White Papers Published in Summer 2014 Editions of Leading Medical Device & Pharmaceutical Publications 3PlaqueTec sichert sich CE-Kennzeichnung für Liquid Biopsy System - bahnbrechende Innovation zur Erfassung neuer biologischer Informationen aus erkranktem Herzkranzgefäß 2PlaqueTec sichert sich CE-Kennzeichnung für Liquid Biopsy System - bahnbrechende Innovation zur Erfassung neuer biologischer Informationen aus erkranktem Herzkranzgefäß 3PlaqueTec sichert sich CE-Kennzeichnung für Liquid Biopsy System - bahnbrechende Innovation zur Erfassung neuer biologischer Informationen aus erkranktem Herzkranzgefäß 4
    ... Prepare for Zingo Launch ... Promoted To Senior Vice President, Marketing and Sales, and ... - Additional Manufacturing Capacity in China -, - Details to be Presented at Investor Briefing Today at ... Time -, ...
    ... TPPII may contribute to obesity by stimulating the formation of ... The enzyme, TPPII, has previously been linked to making people ... it may be even more deeply involved in causing obesity. ... of fat cells in worms and mammalian cells and that ...
    ... Ill. New sol-gel inks developed by researchers at ... to produce three-dimensional structures of metal oxides with nanoscale ... at the nanoscale opens a new avenue to functional ... gas sensors., The researchers describe the new inks in ...
    Cached Biology Technology:Anesiva Outlines Comprehensive Commercialization Plan for FDA Approved Product Zingo(TM) 2Anesiva Outlines Comprehensive Commercialization Plan for FDA Approved Product Zingo(TM) 3Anesiva Outlines Comprehensive Commercialization Plan for FDA Approved Product Zingo(TM) 4Anesiva Outlines Comprehensive Commercialization Plan for FDA Approved Product Zingo(TM) 5Anesiva Outlines Comprehensive Commercialization Plan for FDA Approved Product Zingo(TM) 6Anesiva Outlines Comprehensive Commercialization Plan for FDA Approved Product Zingo(TM) 7Sol-gel inks produce complex shapes with nanoscale features 2
    (Date:7/28/2014)... Reactions among minerals and organic compounds in hydrothermal environments ... they provide energy for the deep biosphere, and may ... little is known about how minerals influence organic reactions. ... have demonstrated how a common mineral acts as a ... need for toxic solvents or expensive reagents. , At ...
    (Date:7/28/2014)... 10 U.S. cities that have seen an increase in ... road closures, overwhelmed storm drains and compromised infrastructure--are on ... report. , This nuisance flooding, caused by rising sea ... 300 and 925 percent since the 1960s. , The ... around the United States, also finds Annapolis and Baltimore, ...
    (Date:7/28/2014)... study found that 73 percent of adult survivors of ... metabolic syndrome and related health problems by failing to ... current issue of the journal Cancer . , ... childhood cancer in the study had metabolic syndrome, an ... pressure, abdominal obesity, elevated triglyceride and other abnormalities that ...
    Breaking Biology News(10 mins):Mineral magic? Common mineral capable of making and breaking bonds 2Mineral magic? Common mineral capable of making and breaking bonds 3NOAA: 'Nuisance flooding' an increasing problem as coastal sea levels rise 2NOAA: 'Nuisance flooding' an increasing problem as coastal sea levels rise 3Unhealthy habits more than double risk of metabolic syndrome in childhood cancer survivors 2Unhealthy habits more than double risk of metabolic syndrome in childhood cancer survivors 3
    ... Md., Sept. 19, 2012  BioFortis Inc., a leading ... research space, today introduced its Next Generation ... It will help pharmaceutical, government and academic ... translational studies to safely and effectively conduct ...
    ... Va.Dr. John P. Holdren, White House Office of Science ... roster of military and government leaders at the Office ... and ASNE Expo, officials announced Sept. 18. Holdren, ... and co-chair of the President,s Council of Advisors on ...
    ... residents with disabilities, along with their families, can look ... Developmental Disabilities Institute (DDI) at Wayne State University. ... from the U.S. Administration for Children and Families. ... contributing to the development of inclusive communities and quality ...
    Cached Biology News:BioFortis Inc., Introduces Next Generation Biobanking Software Platform for Biomarker-Based Clinical Research 2ONR lines up speakers and technologies for 2012 Naval Conference 2Wayne State receives $2.8 million grant from US Administration for Children and Families 2Wayne State receives $2.8 million grant from US Administration for Children and Families 3
    ... Our Accumix standard is a new tuning ... electrospray ionization mass spectrometry. Accumix is ... mass range coverage for both tuning and ... and LTQ-MS) and Fourier transform mass spectrometers. ...
    Determine relative degree of protein binding to phosphoinositides...
    ... Pipette is a synonym for pipetting accuracy, ... design, and superior operating comfort. Its single, ... measuring stroke and blow-out as well as ... ensures utmost accuracy and precision. Ejection sleeve ...
    Goat polyclonal to STMN2 ( Abpromise for all tested applications). Antigen: Synthetic peptide: AKTAMAYKEK, corresponding to C terminal amino acids 2-11 of STMN2. Entrez Gene ID: 11075 Swi...
    Biology Products: